Matt Abernethy - Net Worth and Insider Trading
Matt Abernethy Net Worth
The estimated net worth of Matt Abernethy is at least $5 Million dollars as of 2025-07-08. Matt Abernethy is the CFO of Neurocrine Biosciences Inc and owns about 35,810 shares of Neurocrine Biosciences Inc (NBIX) stock worth over $5 Million. Details can be seen in Matt Abernethy's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Matt Abernethy has not made any transactions after 2025-02-13 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Matt Abernethy
Matt Abernethy Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Matt Abernethy owns 1 companies in total, including Neurocrine Biosciences Inc (NBIX) .
Click here to see the complete history of Matt Abernethy’s form 4 insider trades.
Insider Ownership Summary of Matt Abernethy
| Ticker | Company | Transaction Date | Type of Owner |
|---|---|---|---|
| NBIX | Neurocrine Biosciences Inc | 2025-02-13 | Chief Financial Officer |
Matt Abernethy Latest Holdings Summary
Matt Abernethy currently owns a total of 1 stock. Matt Abernethy owns 35,810 shares of Neurocrine Biosciences Inc (NBIX) as of February 13, 2025, with a value of $5 Million.
Latest Holdings of Matt Abernethy
| Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| NBIX | Neurocrine Biosciences Inc | 2025-02-13 | 35,810 | 129.38 | 4,633,098 |
Holding Weightings of Matt Abernethy
Matt Abernethy Form 4 Trading Tracker
According to the SEC Form 4 filings, Matt Abernethy has made a total of 18 transactions in Neurocrine Biosciences Inc (NBIX) over the past 5 years, including 0 buys and 18 sells. The most-recent trade in Neurocrine Biosciences Inc is the sale of 2,558 shares on February 13, 2025, which brought Matt Abernethy around $298,928.
Insider Trading History of Matt Abernethy
- 1
Matt Abernethy Trading Performance
Matt Abernethy Ownership Network
Ownership Network List of Matt Abernethy
Ownership Network Relation of Matt Abernethy
Matt Abernethy Owned Company Details
What does Neurocrine Biosciences Inc do?
Who are the key executives at Neurocrine Biosciences Inc?
Matt Abernethy is the Chief Financial Officer of Neurocrine Biosciences Inc. Other key executives at Neurocrine Biosciences Inc include Chief Scientific Officer Jude Onyia , Sr VP & Business Development Kevin Charles Gorman , and Chief Medical Officer Eiry Roberts .
Neurocrine Biosciences Inc (NBIX) Insider Trades Summary
Over the past 18 months, Matt Abernethy made 9 insider transaction in Neurocrine Biosciences Inc (NBIX) with a net sale of 54,716. Other recent insider transactions involving Neurocrine Biosciences Inc (NBIX) include a net sale of 33,548 shares made by Ingrid Delaet , a net sale of 345,254 shares made by Kevin Charles Gorman , and a net sale of 178,724 shares made by Eric Benevich .
In summary, during the past 3 months, insiders sold 59,975 shares of Neurocrine Biosciences Inc (NBIX) in total and bought 0 shares, with a net sale of 59,975 shares. During the past 18 months, 1,015,054 shares of Neurocrine Biosciences Inc (NBIX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,015,054 shares.
Neurocrine Biosciences Inc (NBIX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Neurocrine Biosciences Inc Insider Transactions
Matt Abernethy Mailing Address
Above is the net worth, insider trading, and ownership report for Matt Abernethy. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Matt Abernethy's mailing address is: San Diego Ca 92121.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
